Please login to the form below

Not currently logged in
Email:
Password:

Roche to buy Anadys for $230m

Roche is to acquire US-based Anadys Pharmaceuticals for $230m, developing the company's hepatitis C capabilities

Roche is to acquire US-based Anadys Pharmaceuticals for $3.70 per share – about $230m in total.

Anadys specialises in the development of oral, small molecule therapeutics for the potential treatment of hepatitis C virus infection.

The deal will see Roche take ownership of the drug candidate setrobuvir (ANA598), which is currently in a phase II study in combination with Roche's (Pegasys) pegylated interferon and (Copegus) ribavirin.

Other products in development include ANA773, which is currently at phase I trial stage for the treatment of hepatitis C as well as other chronic infections and cancer.

Jean-Jacques Garaud, global head of Roche pharmaceutical research and early development, said the acquisition would enhance the company's presence in the treatment of hepatitis C.

He said: "Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon."

17th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics